BIOS BioPlus Acquisition Corporation

Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and AdventHealth Orlando, a nationally-ranked hospital system in Florida, today announced the availability of the Guardian™ System, the first and only FDA-approved implantable heart attack detection and warning system, at AdventHealth Orlando.

The Guardian System, developed by Avertix, is designed to detect acute coronary syndrome events, such as heart attacks, in real-time, including silent and atypical symptomatic heart attacks, and provide life-saving alerts to patients and healthcare professionals. The Guardian, indicated for patients with a prior acute coronary syndrome event, captures cardiac signals from inside the heart, providing enhanced accuracy and fidelity and can help prevent unnecessary trips to the emergency room, enabling physicians with individualized and up-to-date data for seamless, personalized patient care. With its patient-specific detection, powered by machine learning, the Guardian real-time insights offer an innovative solution that empowers both healthcare providers and patients to actively monitor and manage their cardiovascular health outcomes.

Dr. Usman Siddiqui, medical director of electrophysiology at AdventHealth’s hospitals in Celebration and Kissimmee, successfully conducted Central Florida’s first Guardian implant procedure at AdventHealth Orlando. As the number one rated hospital in Central Florida, AdventHealth Orlando continues to pioneer medical advancements with the aim of delivering exceptional, whole-person care. By offering the Guardian System, the hospital further solidifies its commitment to providing innovative and transformative solutions for cardiac patients.

"I believe the Guardian System introduces a significant advancement in cardiac care, potentially transforming how we detect heart attacks,” Dr. Siddiqui said. “I am excited to be involved in an innovative approach to cardiac care and look forward to witnessing how it can improve the well-being of patients in need of continuous heart monitoring.”

According to the World Health Organization, cardiovascular diseases are the leading cause of death globally. In the U.S., the Centers for Disease Control and Prevention (CDC) also reports that heart disease is the leading cause of death, with over 800,000 heart attacks every year, and approximately 25% of heart attack survivors will experience a second heart attack within five years of their first.

"We are proud to partner with AdventHealth Orlando to introduce the Guardian System to their respected hospital," said Tim Moran, President and Chief Executive Officer of Avertix. "This collaboration highlights our shared commitment to delivering purpose-driven, innovative healthcare solutions for cardiac care patients. We’re working together to empower patients to live an enhanced quality of life, one without the fear of a potential second heart attack, while also providing clinicians with the tools they need to deliver personalized and compassionate care."

On May 3, 2023, Avertix Medical, Inc. and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) (“BIOS”) (Nasdaq: BIOS), a special purpose acquisition company, announced that they entered into a definitive merger agreement (the “Transaction”). Upon completion of the transaction, the combined company’s securities are expected to be listed on Nasdaq under the ticker symbol “AVRT.”

About Avertix Medical, Inc.

Avertix is a cutting-edge medical device company offering the first and only FDA-approved Class III implantable device that can detect silent and atypical symptomatic heart attacks in real-time. With a robust portfolio of U.S. patents pertaining to Acute Coronary Syndrome (ACS) events, Avertix is at the forefront of innovation in cardiovascular care and is committed to improving patient outcomes and saving lives through advanced medical technologies. For more information, visit avertix.com.

About AdventHealth Orlando

About the AdventHealth Central Florida Division: AdventHealth’s Central Florida Division encompasses more than 20 hospitals and ERs in the six counties in and surrounding metro Orlando. The world-class hospitals, combined with a comprehensive outpatient care network, see more than 5.7 million patient visits annually.  

AdventHealth also has an expansive research portfolio in Central Florida, with more than 500 clinical trials and studies in progress. 

The organization has a deep commitment to serving the community and has a local financial impact of more than $1 billion annually. AdventHealth and its employees are responsible for nearly 20 percent of Central Florida’s economy.  

The division’s flagship campus — AdventHealth Orlando — boasts nationally and internationally recognized programs, and serves as a major tertiary and quaternary referral hospital for much of the Southeast, the Caribbean and Latin America. Quality specialty care is provided through AdventHealth Institutes, which is nationally recognized in numerous specialties. 

AdventHealth Orlando has been recognized by U.S. News & World Report, Newsweek, Centers for Medicare and Medicaid Services, and the Leapfrog Group. 

Learn more about the Central Florida Division on our Newsroom. 

Important Information

BIOS has filed with the Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4 (as amended or supplemented, the “Registration Statement”), which includes a preliminary proxy statement/prospectus of BIOS, that when finalized in definitive format will be both the proxy statement to be distributed to holders of BIOS’ ordinary shares in connection with the solicitation of proxies for the vote by BIOS‘ shareholders with respect to the proposed Transaction and related matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued in the Transaction. After the Registration Statement is declared effective, BIOS will mail a definitive proxy statement/prospectus and other relevant documents to its shareholders. BIOS shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus, and amendments thereto, and the definitive proxy statement/prospectus in connection with BIOS’ solicitation of proxies for its shareholders’ meeting to be held to approve the Transaction and related matters because the proxy statement/prospectus will contain important information about BIOS and Avertix and the proposed Transaction.

The definitive proxy statement/prospectus will be mailed to shareholders of BIOS as of a record date to be established for voting on the proposed Transaction and related matters. Shareholders may obtain copies of the proxy statement/prospectus, when available, without charge, at the SEC’s website at www.sec.gov or by directing a request to: BioPlus Acquisition Corp., 260 Madison Avenue, Suite 800, New York, NY 10026 or by emailing info@Biosspac.com.

Forward-Looking Statements

Certain statements included in this Press Release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “would,” “plan,” “potential,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. All statements, other than statements of present or historical fact included in this Press Release, regarding BIOS’ proposed acquisition of Avertix, BIOS’ ability to consummate the proposed transactions, the benefits of the proposed transactions and the combined company’s future financial performance as well as the combined company’s strategy, the benefits of the partnership with AdventHealth Orlando, and among others, are forward-looking statements. These statements are based on various assumptions, whether or not identified in this Press Release, and on the current expectations of Avertix’s management and are not predictions of actual performance, and, as a result, are subject to risks and uncertainties. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this Press Release, including but not limited to: the inability of the parties to successfully or timely consummate the Transaction; the risk that the Transaction may not be completed by BIOS’ business combination deadline and the potential failure to obtain an extension of the business combination deadline by BIOS; failure to realize the anticipated benefits of the Transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement; Avertix’s history of operating losses; Avertix’s ability to engage physicians to utilize and prescribe its solution; changes in reimbursement practices; technological changes in Avertix’s market; Avertix’s ability to protect its intellectual property; Avertix 's material weaknesses in financial reporting; and the Avertix’s ability to navigate complex regulatory requirements. Please carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section in the preliminary proxy statement/prospectus in the Registration Statement and other documents filed or that may be filed by BIOS from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Participants in the Solicitation

This press release is not a solicitation of a proxy from any investor or securityholder. However, BIOS and Avertix and their respective directors, officers and other members of their management and employees may be deemed to be participants in the solicitation of proxies from BIOS’ shareholders with respect to the proposed business combination and related matters. Investors and securityholders may obtain more detailed information regarding the names, affiliations and interests of the directors and officers of BIOS and Avertix relating to the Transaction in the preliminary proxy statement/prospectus contained in the Registration Statement. These documents may be obtained free of charge from the sources indicated above.

No Offer or Solicitation

This press release is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy or subscribe for any securities or a solicitation of any vote of approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Contacts

Media RelationsSean LeousICR WestwickeSean.Leous@westwicke.com+1-646-866-4012

Holly Windlermedia@avertix.com

Investor RelationsMike CavanaughICR WestwickeMike.Cavanaugh@westwicke.com +1-617-877-9641